Introduction
Genocea Biosciences (GNCA) is a clinical-stage biotech company working on developing novel cancer immunotherapies. With its proprietary discovery platform, ATLAS, the company can identify immunotherapy targets based on an individual's tumor antigen-specific T cell responses which results in more personalized cancer immunotherapies.
ATLAS Platform
Recently, immunotherapy has emerged as a novel and effective way of treating cancer by activating or suppressing the immune system. Examples of immunotherapy include checkpoint inhibitor which works by blocking checkpoint proteins from binding with their partner proteins, which otherwise would prevent the T cells to attack the